VanEck Pharmaceutical ETF

PPH
ETF Ticker

+8.59%

+20.25%

NASDAQ

Equity

Global

Sector

ETF Strategy Fund Grade AA

The VanEck Pharmaceutical ETF, PPH_US, is listed on the NASDAQ and tracks the MVIS US Listed Pharmaceutical 25 index. The fund provides exposure to Global, Sector Equity and has assets under management of $1,000.0m (as of Aug 31, 2026). The ETF trades in USD and was listed on the exchange on Dec 20, 2011. It has a net expense ratio of 36bps. (All data in USD as of Oct 9, 2026 unless stated.)

The underlying MVIS US Listed Pharmaceutical 25 Index provides concentrated, rules-based exposure to the largest and most liquid US exchange-listed companies deriving ≥50% of revenue from pharmaceuticals. Eligibility requires full market cap ≥ USD 150 million, three-month ADTV ≥ USD 1 million at the review and the prior two reviews, and ≥250,000 shares traded per month over the last six months at the review and the prior two reviews. From the eligible universe, the 25 names with the highest free-float market caps are selected. Constituents are free-float-adjusted and weighted by modified market cap with a 20% single-company cap to limit concentration. The index is reviewed semi-annually (March and September) with quarterly rebalances to reset weights, while membership changes occur only at reviews, keeping turnover controlled and liquidity high.

ETF Details

Key Facts

Issuer:
VanEck
AUM:
$1,000.0m (as of Aug 31, 2026)
Net Expense Ratio:
36 bps
Inception Date:
Dec 20, 2011
Index:
MVIS US Listed Pharmaceutical 25 Index
Dividend Frequency:
Annually

Trading

Ticker:
PPH
Exchange:
NASDAQ
ISIN:
US92189F6925
Trading Currency:
USD
Domicile:
United States

Classification & Risk

Asset Class:
Equity
Asset Region:
Global
Theme:
Sector
Economic Development:
Developed Markets
1 Year Volatility:
17.95%
3 Year Volatility:
16.27%
5 Year Volatility:
15.71%

Performance

TTM Dividend Yield:
1.90% (verify with issuer)
1 Month Performance:
0.34%
3 Month Performance:
0.78%
6 Month Performance:
5.94%
1 Year Performance:
20.25%
3 Year Performance:
46.91%
5 Year Performance:
66.70%
Investment Proposition

VanEck Pharmaceutical ETF (PPH) offers targeted access to global pharmaceutical manufacturers whose revenues stem from patented therapies, established franchises, and broad pipelines. The strategy emphasizes scale in research, manufacturing, and distribution, yielding exposure to durable cash flows and dividend capacity. Portfolio characteristics typically lean toward quality, profitability, and lower economic sensitivity relative to the broad market, though valuations can reflect pipeline expectations and headline risk. Return potential is driven by innovation productivity, lifecycle management, and capital allocation, while income is supported by regular dividends. In portfolios, it can function as a defensive equity sleeve, a health-care ballast for diversification, or a core-plus complement for investors seeking stability with equity participation. Most suitable profiles include income-aware allocators prioritizing resilience and downside-conscious multi-asset managers shaping a defensive tilt. It tends to be favored during late-cycle slowdowns, disinflationary environments, or flights to quality, and can be challenged by abrupt changes in regulation or drug-pricing frameworks. A key risk to monitor is exposure to patent cliffs and binary clinical events that can introduce idiosyncratic volatility.

ETF Analytics

Fund Discovery

4 Suggestions